Clinical Trial Update: Safety and Efficacy Study of IV Ganaxolone as Adjuvant Therapy for Established Status Epilepticus (ESE) [Phase 2]

View source ↗

Summary

The Phase 2 trial evaluating IV ganaxolone as adjuvant therapy for established status epilepticus has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Status Epilepticus

Drugs mentioned

• ganaxolone (ganaxolone)

Snippet

Sponsor: Marinus Pharmaceuticals | Conditions: Status Epilepticus | Phase 2 | Status: WITHDRAWN